Eli Lilly Record at $1 Trillion as GLP-1 Boom Lifts LLY
Can Eli Lilly’s record run keep defying gravity as GLP-1 dominance and billion-dollar dealmaking reshape Big Pharma? Maik Kemper Editor in Chief Lilly’s AI-infused commercial engine is now…
Novo Nordisk Wegovy Hits 3M U.S. Prescriptions in 22 Weeks
Has Novo Nordisk Wegovy just delivered the prescription surge that forces Wall Street to rethink the entire obesity trade? Maik Kemper Editor in Chief The oral Wegovy tablet…
Novo Nordisk Wegovy Faces a Warning in the Obesity Race
Can Novo Nordisk Wegovy regain momentum fast enough to challenge Eli Lilly before the next wave of obesity drugs resets the market? Maik Kemper Editor in Chief Oral…
Novo Nordisk Wegovy Falls 4.5% on Pipeline Warning
Can Novo Nordisk Wegovy keep its obesity lead if Wall Street starts caring more about the next drug than today’s sales? Maik Kemper Editor in Chief With the…
Novo Nordisk ADA +2.3%: CagriSema Data Back in Focus
Can Novo Nordisk ADA data finally give investors a reason to believe the GLP-1 leader can regain momentum? Maik Kemper Editor in Chief The conference highlights the strength…
Novo Nordisk FDA Compounding +4.8% Surge Shakes GLP‑1 Rivals
Will the Novo Nordisk FDA Compounding crackdown finally shut down GLP‑1 copycats and supercharge the branded obesity drug boom? Maik Kemper Editor in Chief When FDA‑approved drugs are…
Novo Nordisk AI Partnership Boom: Can It Close the Obesity Gap?
Can the Novo Nordisk AI Partnership with OpenAI turn a battered obesity champion into the next big winner of the healthcare AI boom? Maik Kemper Editor in Chief…
Eli Lilly Weight-Loss Strategy vs Novo: Price War Shock
Can the Eli Lilly Weight-Loss Strategy stay on top as Novo Nordisk slashes prices and AI reshapes the obesity drug race? Maik Kemper Editor in Chief Conclusion In…
Novo Nordisk Wegovy Strategy Boom With HD Dose Push
Can Novo Nordisk’s aggressive Wegovy strategy really outflank Eli Lilly in the GLP-1 obesity war before new rivals scale up? Maik Kemper Editor in Chief The Wegovy HD…
Hims & Hers GLP-1 partnership sparks new weight-loss boom
Can the Hims & Hers GLP-1 partnership with Novo Nordisk turn telehealth weight loss into the company’s next major growth engine? Maik Kemper Editor in Chief When healthcare…